Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade

被引：0
|
作者：
Tang, Haidong [1 ]
Wang, Yang [1 ]
Chlewicki, Lukasz K. [2 ]
Zhang, Yuan [2 ]
Fu, Yang-Xin [1 ,2 ]
机构：
[1] Univ Texas Southwestern Med Ctr, Dallas, TX USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF IMMUNOLOGY | 2016年 / 196卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
    Moore, Ellen
    Clavijo, Paul E.
    Davis, Ruth
    Cash, Harrison
    Van Waes, Carter
    Kim, Young
    Allen, Clint
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (12) : 1061 - 1071
  • [32] Eradication of Non-T Cell-Inflamed Tumors by in Situ Immunomodulation with PD-L1 Blockade
    Oba, Takaaki
    Keler, Tibor
    Marsh, Henry C.
    Minderman, Hans
    Abrams, Scott
    Ito, Fumito
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (04) : E53 - E54
  • [33] Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy
    Huang, Shuang
    Zhou, Nianxin
    Zhao, Linjie
    Gimple, Ryan C.
    Ahn, Young Ha
    Zhang, Peidong
    Wang, Wei
    Shao, Bin
    Yang, Jingyun
    Zhang, Qian
    Zhao, Sai
    Jiang, Xuehan
    Chen, Zhiwei
    Zeng, Yangfan
    Hu, Hongbo
    Gustafsson, Jan-Ake
    Zhou, Shengtao
    ISCIENCE, 2020, 23 (09)
  • [34] Linked CD4+/CD8+T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression
    Dolina, Joseph S.
    Lee, Joey
    Brightman, Spencer E.
    McArdle, Sara
    Hall, Samantha M.
    Thota, Rukman R.
    Zavala, Karla S.
    Lanka, Manasa
    Premlal, Ashmitaa Logandha Ramamoorthy
    Greenbaum, Jason A.
    Cohen, Ezra E. W.
    Peters, Bjoern
    Schoenberger, Stephen P.
    JOURNAL OF CLINICAL INVESTIGATION, 2023, 133 (17):
  • [35] Difference of Tumor Mutational Burden Is Associated with Distinct Immune Microenviroment in the T Cell-Inflamed Lung Adenocarcinoma
    Karasaki, T.
    Kitano, K.
    Nagayama, K.
    Nitadori, J.
    Sato, M.
    Anraku, M.
    Kakimi, K.
    Nakajima, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S423 - S423
  • [36] SOX2 EXPRESSION IN NSCLC MEDIATES CHANGES IN THE TUMOR MICROENVIRONMENT IMPAIRING T CELL INFILTRATION AND PROMOTING RESISTANCE TO CHECKPOINT BLOCKADE THERAPY
    Spranger, Stefani
    Bhutkar, Arjun
    Nguyen, Kim
    Weng, Sally
    Duong, Ellen
    Blatt, Sarah
    Torres-Mejia, Elen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1524 - A1524
  • [37] The temporal influence of the tumor microenvironment in response to checkpoint blockade
    Greenwald, Noah F.
    Nederlof, Iris
    Horlings, Hugo
    Kok, Marleen
    Curtis, Christina
    Angelo, Michael
    CANCER RESEARCH, 2024, 84 (06)
  • [38] The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
    Petitprez, Florent
    Meylan, Maxime
    de Reynies, Aurelien
    Sautes-Fridman, Catherine
    Fridman, Wolf H.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [39] Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
    Xu, Lijun
    Li, Bingyu
    Pi, Chenyu
    Zhu, Zhaohua
    Tao, Fei
    Xie, Kun
    Feng, Yan
    Xu, Xiaoqing
    Yin, Yanxin
    Gu, Hua
    Fang, Jianmin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (12)
  • [40] TUMOR-INTRINSIC P38 SIGNALING AS A THERAPEUTIC TARGET TO OVERCOME NON-T CELL-INFLAMED TUMORS AND IMMUNOTHERAPY RESISTANCE
    Dadey, Rebekah
    Winski, Shannon
    Lee, Patrice
    Brodeur, Sarah
    Bruno, Tullia
    Skinner, Heath
    Ferris, Robert
    Luke, Jason
    Bao, Riyue
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A946 - A946
12345